OverviewSuggest Edit

EyePoint Pharmaceuticals (formerly pSivida) is a pharmaceutical company focused on the development of innovative miniaturized, sustained-release drug delivery products and technologies to treat serious, debilitating diseases of the eye that can lead to blindness. It is focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, Durasert and BioSilicon. The injectable, sustained release micro-insert ILUVIEN for the treatment of chronic Diabetic Macula Edema (DME), licensed to Alimera Sciences, Inc., and utilizes the third generation of the Durasert technology. The Company's two FDA-approved products, Retisert and Vitrasert, are implants that provide long-term, sustained drug delivery to treat two other chronic diseases of the retina.

TypePublic
Founded1987
HQWatertown, US
Websiteeyepointpharma.com

Latest Updates

Employees (est.) (Mar 2019)55(+25%)
Revenue (FY, 2018)$2.9 M(-61%)
Share Price (Jan 2020)$1.7

Key People/Management at EyePoint Pharmaceuticals

Ron Honig

Ron Honig

Senior Vice President, General Counsel & Company Secretary
Nancy Lurker

Nancy Lurker

President & Chief Executive Officer
George O. Elston

George O. Elston

Chief Financial Officer and Head of Corporate Development
Scott Jones

Scott Jones

Chief Commercial Oficer
Said Saim

Said Saim

Chief Technology Officer
Show more

EyePoint Pharmaceuticals Office Locations

EyePoint Pharmaceuticals has an office in Watertown
Watertown, US (HQ)
480 Pleasant St b300
Show all (1)

EyePoint Pharmaceuticals Financials and Metrics

EyePoint Pharmaceuticals Revenue

EyePoint Pharmaceuticals's revenue was reported to be $2.93 m in FY, 2018
USD

Revenue (Q3, 2019)

2.5m

Net income (Q3, 2019)

(15.6m)

EBIT (Q3, 2019)

(14.1m)

Market capitalization (20-Jan-2020)

183.8m

Closing stock price (20-Jan-2020)

1.7

Cash (30-Sept-2019)

31.8m

EV

198.8m
EyePoint Pharmaceuticals's current market capitalization is $183.8 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

3.5m2.1m3.5m26.6m1.6m7.5m2.9m

Revenue growth, %

665%(94%)

Sales and marketing expense

8.2m

General and administrative expense

6.9m7.2m7.5m8.1m9.0m11.2m8.9m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q1, 2019Q2, 2019Q3, 2019

Revenue

1.7m630.0k538.0k553.0k585.0k513.0k597.0k592.0k2.0m25.3m521.0k328.0k466.0k526.0k324.0k277.0k6.0m590.0k385.0k933.0k928.0k486.0k2.0m7.2m2.5m

Cost of goods sold

330.0k706.0k

Gross profit

1.7m6.5m

Gross profit Margin, %

84%90%
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

4.6m6.9m15.3m19.1m15.3m16.9m45.3m

Accounts Receivable

967.0k597.0k11.9m251.0k627.0k

Prepaid Expenses

421.0k1.6m591.0k1.4m

Inventories

547.0k681.0k483.0k279.0k
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(24.8m)(11.9m)(13.4m)6.3m(21.5m)(18.5m)(44.7m)

Depreciation and Amortization

190.0k225.0k139.0k112.0k152.0k815.0k1.3m

Inventories

1.1m(136.0k)187.0k(279.0k)

Accounts Payable

64.0k277.0k(213.0k)292.0k626.0k(346.0k)(298.0k)
USDY, 2019

EV/EBIT

-14.1 x

EV/CFO

-4.4 x

Debt/Equity

2.9 x

Debt/Assets

0.6 x

Financial Leverage

5 x
Show all financial metrics

EyePoint Pharmaceuticals Online and Social Media Presence

Embed Graph

EyePoint Pharmaceuticals News and Updates

EyePoint Pharmaceuticals Announces YUTIQ® Presentations at the American Academy of Ophthalmology 2019 Annual Meeting

WATERTOWN, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that two abstracts supporting the Company's YUTIQ® (fluocinolone ace…

EyePoint Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Company Progress

- YUTIQ™ and DEXYCU™ commercially launched in 1Q2019 –

EyePoint Pharmaceuticals to Present at Upcoming Medical Conferences

Two Presentations Highlighting YUTIQ™ to be Presented at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Show more

EyePoint Pharmaceuticals Frequently Asked Questions

  • When was EyePoint Pharmaceuticals founded?

    EyePoint Pharmaceuticals was founded in 1987.

  • Who are EyePoint Pharmaceuticals key executives?

    EyePoint Pharmaceuticals's key executives are Ron Honig, Nancy Lurker and George O. Elston.

  • How many employees does EyePoint Pharmaceuticals have?

    EyePoint Pharmaceuticals has 55 employees.

  • What is EyePoint Pharmaceuticals revenue?

    Latest EyePoint Pharmaceuticals annual revenue is $2.9 m.

  • What is EyePoint Pharmaceuticals revenue per employee?

    Latest EyePoint Pharmaceuticals revenue per employee is $53.2 k.

  • Who are EyePoint Pharmaceuticals competitors?

    Competitors of EyePoint Pharmaceuticals include Faes Farma, AbbVie and Vifor Pharma.

  • Where is EyePoint Pharmaceuticals headquarters?

    EyePoint Pharmaceuticals headquarters is located at 480 Pleasant St b300, Watertown.

  • Where are EyePoint Pharmaceuticals offices?

    EyePoint Pharmaceuticals has an office in Watertown.

  • How many offices does EyePoint Pharmaceuticals have?

    EyePoint Pharmaceuticals has 1 office.